STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2012-04-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-11-0801PMID 22532597
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abstract LB-400: STAT3 mediates resistance to MEK inhibitor through microRNA miR-17

  2011cited by this paper
• Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines.

  2011cited by this paper
• Benefits of interferon‐β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter

  2011cited by this paper
• Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter : a multicenter study

  2011cited by this paper
• miR-195, miR-455-3p and miR-10a* are implicated in acquired temozolomide resistance in glioblastoma multiforme cells

  2011cited by this paper
• A population of BJ fibroblasts escaped from Ras-induced senescence susceptible to transformation.

  2011cited by this paper
• STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer.

  2010cited by this paper
• MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.

  2010cited by this paper
• miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.

  2010cited by this paper
• The transcriptional network for mesenchymal transformation of brain tumours

  2010influential reference
• IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines

  2010cited by this paper
• Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

  2010cited by this paper
• Caffeine Confers Radiosensitization of PTEN-Deficient Malignant Glioma Cells by Enhancing Ionizing Radiation–Induced G1 Arrest and Negatively Regulating Akt Phosphorylation

  2010cited by this paper
• Exciting New Advances in Neuro‐Oncology: The Avenue to a Cure for Malignant Glioma

  2010cited by this paper
• High Incidence of MGMT and RARβ Promoter Methylation in Primary Glioblastomas: Association with Histopathological Characteristics, Inflammatory Mediators and Clinical Outcome

  2010cited by this paper
• Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.

  2009influential reference
• The transcriptional network for mesenchymal transformation of brain tumors

  2009cited by this paper
• Stat3 activation is required for the growth of U87 cell-derived tumours in mice.

  2009cited by this paper
• Signaling in Malignant Astrocytomas: Role of Neural Stem Cells and Its Therapeutic Implications

  2009cited by this paper
• Mechanisms of Disease: temozolomide and glioblastoma—look to the future

  2008cited by this paper
• Constitutively Activated STAT3 Frequently Coexpresses with Epidermal Growth Factor Receptor in High-Grade Gliomas and Targeting STAT3 Sensitizes Them to Iressa and Alkylators

  2008influential reference
• Careful Exclusion of Non-neoplastic Brain Components is Required for an Appropriate Evaluation of O6-methylguanine-DNA Methyltransferase Status in Glioma: Relationship Between Immunohistochemistry and Methylation Analysis

  2008cited by this paper
• The Incidence, Correlation with Tumor-Infiltrating Inflammation, and Prognosis of Phosphorylated STAT3 Expression in Human Gliomas

  2008cited by this paper
• Autocrine IL-6 signaling: a key event in tumorigenesis?

  2008cited by this paper
• Signal Transducer and Activator of Transcription-3: A Molecular Hub for Signaling Pathways in Gliomas

  2008cited by this paper
• STAT3 inhibits the degradation of HIF-1α by pVHL-mediated ubiquitination

  2008cited by this paper
• STAT3 inhibits the degradation of HIF-1alpha by pVHL-mediated ubiquitination.

  2008cited by this paper
• Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.

  2007cited by this paper
• The 2007 WHO Classification of Tumours of the Central Nervous System

  2007cited by this paper
• Malignant astrocytic glioma: genetics, biology, and paths to treatment.

  2007cited by this paper
• The therapeutic potential of O6-alkylguanine DNA alkyltransferase inhibitors

  2007cited by this paper
• WHO classification of tumours of the central nervous system

  2007cited by this paper
• O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies

  2007cited by this paper
• Signaling adaptor protein Crk is indispensable for malignant feature of glioblastoma cell line KMG4.

  2007cited by this paper
• The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor.

  2006cited by this paper
• MGMT Gene Silencing and Benefit From Temozolomide in GlioblastomaHegi ME, Diserens A-C, Gorlia T, et al (Univ Hosp Lausanne, Switzerland; Univ Hosp Geneva; Swiss Inst for Experimental Cancer Research, Epalinges, Switzerland; et al) N Engl J Med 352:997–1003, 2005§

  2006cited by this paper
• O6‐methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells

  2006cited by this paper
• Primary Glioblastomas Express Mesenchymal Stem-Like Properties

  2006cited by this paper
• Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

  2006cited by this paper
• Lomeguatrib, a Potent Inhibitor of O6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors

  2006cited by this paper
• PDGF receptor tyrosine kinase inhibitor suppresses mesangial cell proliferation involving STAT3 activation

  2006cited by this paper
• IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.

  2005cited by this paper
• Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair–deficient malignant glioma xenograft

  2005cited by this paper
• The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death.

  2005cited by this paper
• MGMT gene silencing and benefit from temozolomide in glioblastoma.

  2005cited by this paper
• Altered molecular pathways in gliomas: an overview of clinically relevant issues.

  2004cited by this paper
• The STATs of cancer — new molecular targets come of age

  2004cited by this paper
• Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation

  2003cited by this paper
• Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis

  2003cited by this paper
• Stat proteins and oncogenesis.

  2002cited by this paper
• Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

  2002cited by this paper
• Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.

  2001cited by this paper
• Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

  2000cited by this paper
• Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling

  2000cited by this paper
• A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.

  1999cited by this paper
• Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.

  1999cited by this paper
• Frequent Co‐Alterations of TP53, p16/CDKN2A, p14ARF, PTEN Tumor Suppressor Genes in Human Glioma Cell Lines.

  1999cited by this paper
• Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide

  1999cited by this paper
• Expression of matrix metalloproteinases in human glioma cell lines in the presence of IL-10

  1998cited by this paper
• Genetic instability leads to loss of both p53 alleles in a human glioblastoma

  1998cited by this paper
• Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein.

  1995cited by this paper

• Siramesine induced cell death of glioblastoma through inactivating the STAT3-MGMT signaling pathway

  2025cites this paper
• Advances in tumor-associated macrophage-mediated chemotherapeutic resistance in glioma

  2025cites this paper
• STAT3 axis in cancer and cancer stem cells: From oncogenesis to targeted therapies.

  2025cites this paper
• Fixed-point cleaved bioinspired nanosystem via promoting LAT1-mediated BBB penetration for spatiotemporal therapy in TMZ resistant glioblastoma

  2025cites this paper
• α-synuclein expression in glioblastoma restores tumor suppressor function and rescues temozolomide drug resistance

  2025cites this paper
• IL-19 as a promising theranostic target to reprogram the glioblastoma immunosuppressive microenvironment

  2025cites this paper
• Enhancer RNA from STAT3 locus affects temozolomide chemoresistance of glioblastoma cells.

  2025cites this paper
• Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide.

  2025cites this paper
• DNA repair and the contribution to chemotherapy resistance

  2025cites this paper
• Glioblastoma at the crossroads: current understanding and future therapeutic horizons

  2025cites this paper
• Proinflammatory macrophage secretome enhances temozolomide sensitivity in glioblastoma via pSTAT3-mediated downregulation of DNA repair enzymes

  2025cites this paper
• O6-methylguanine DNA methyltransferase (MGMT) expression in U1242 glioblastoma cells enhances in vitro clonogenicity, tumor implantation in vivo, and sensitivity to alisertib-carboplatin combination treatment

  2025cites this paper
• Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastoma

  2024cites this paper
• Examination of MGMT as a risk gene for dementia in the Amish

  2024cites this paper
• AP-2α decreases TMZ resistance of recurrent GBM by downregulating MGMT expression and improving DNA damage.

  2024cites this paper
• Unraveling the mysteries of MGMT: Implications for neuroendocrine tumors.

  2024cites this paper
• Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT

  2024cites this paper
• Pyrimidine compounds BY4003 and BY4008 inhibit glioblastoma cells growth via modulating JAK3/STAT3 signaling pathway

  2024cites this paper
• Albumin-Based Microneedles for Spatiotemporal Delivery of Temozolomide and Niclosamide to Resistant Glioblastoma.

  2024cites this paper
• Selective regulation of chemosensitivity in glioblastoma by phosphatidylinositol 3-kinase beta

  2024cites this paper
• RND1 inhibits epithelial-mesenchymal transition and temozolomide resistance of glioblastoma via AKT/GSK3-β pathway

  2024cites this paper
• STAT3 phosphorylation inhibitor Bt354 exhibits anti‐neoplastic activity in glioblastoma multiforme cells

  2024cites this paper
• MGMT in TMZ-based glioma therapy: Multifaceted insights and clinical trial perspectives.

  2024cites this paper
• Microneedle Patch Delivery of PLCG1-siRNA Efficient Enhanced Temozolomide Therapy for Glioblastoma.

  2024cites this paper
• Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment

  2024cites this paper
• Nucleic acid drug vectors for diagnosis and treatment of brain diseases

  2023cites this paper
• Synergistic effect of cryptotanshinone and temozolomide treatment against human glioblastoma cells

  2023cites this paper
• Specific Transport of Temozolomide Does Not Override DNA Repair-mediated Chemoresistance.

  2023cites this paper
• Autophagy Modulation and Its Implications on Glioblastoma Treatment

  2023cites this paper
• Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide

  2023cites this paper
• HOXD‐AS2‐STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma

  2023cites this paper
• EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT.

  2023cites this paper
• Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation

  2023cites this paper
• Development and Validation of a Targeted Treatment for Brain Tumors Using a Multi-Drug Loaded, Relapse-Resistant Polymeric Theranostic.

  2023cites this paper
• Exploring the Use of Cold Atmospheric Plasma to Overcome Drug Resistance in Cancer

  2023cites this paper
• Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas

  2023cites this paper
• An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?

  2023cites this paper
• Radiotherapy opens the blood-brain barrier and synergizes with anlotinib in treating glioblastoma.

  2023cites this paper
• Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition

  2023cites this paper
• Roles of STAT3 in the pathogenesis and treatment of glioblastoma

  2023cites this paper
• Silibinin plus Stupp protocol as conversion therapy for unresectable glioblastoma with pSTAT3 expression, an oasis in the desert? A case report description.

  2023cites this paper
• Tumor-derived exosomes reversing TMZ resistance by synergistic drug delivery for glioma-targeting treatment.

  2022cites this paper
• Computer analysis of regulation of hepatocarcinoma marker genes hypermethylated by HCV proteins

  2022cites this paper
• Characterization of EGFR-reprogrammable temozolomide-resistant cells in a model of glioblastoma

  2022influential citation
• World Journal of Methodology system and crosstalk: A review of the available

  2022cites this paper
• Role of the circulatory interleukin-6 in the pathogenesis of gliomas: A systematic review

  2022cites this paper
• Drug delivery in glioblastoma therapy: a review on nanoparticles targeting MGMT-mediated resistance

  2022cites this paper
• Involvement of cell shape and lipid metabolism in glioblastoma resistance to temozolomide

  2022cites this paper
• A case of psoriasiform drug eruption caused by temozolomide

  2022cites this paper
• Chaperone protein P4HB predicts temozolomide response and prognosis in malignant glioma.

  2022cites this paper
• A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma

  2022cites this paper
• Alterations in Molecular Profiles Affecting Glioblastoma Resistance to Radiochemotherapy: Where Does the Good Go?

  2022cites this paper
• Heme Oxygenase-1 targeting exosomes for temozolomide resistant glioblastoma synergistic therapy.

  2022cites this paper
• MV1035 Overcomes Temozolomide Resistance in Patient-Derived Glioblastoma Stem Cell Lines

  2022cites this paper
• Temozolomide Treatment Induces HMGB1 to Promote the Formation of Glioma Stem Cells via the TLR2/NEAT1/Wnt Pathway in Glioblastoma

  2021cites this paper
• MicroRNAs Regulate Cell Cycle and Cell Death Pathways in Glioblastoma

  2021cites this paper
• Transcription factors in glioblastoma - Molecular pathogenesis and clinical implications.

  2021cites this paper
• A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma

  2021cites this paper
• Cation‐Free siRNA Micelles as Effective Drug Delivery Platform and Potent RNAi Nanomedicines for Glioblastoma Therapy

  2021cites this paper
• Prognostic and Clinical Values of Chaperone Protein P4HB in Malignant Glioma

  2021cites this paper
• Molecular mechanisms in temozolomide-resistant glioblastoma

  2021cites this paper
• Understanding signal transduction pathways to overcome targeted therapy resistance in glioblastoma

  2021cites this paper
• Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance

  2021cites this paper
• Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy

  2021cites this paper
• Establishment of Patient-Derived Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response

  2021cites this paper
• LncRNA SNHG11 Promotes Temozolomide Resistance in Glioblastoma via Promoting MGMT Expression

  2021cites this paper
• SD‐36 promotes growth inhibition and induces apoptosis via suppression of Mcl‐1 in glioma

  2021cites this paper
• Anti-Tumor Functions of Prelatent Antithrombin on Glioblastoma Multiforme Cells

  2021cites this paper
• Application of the antitussive agents oxelaidin and butamirate as anti-glioma agents

  2021cites this paper
• SH2B3, Transcribed by STAT1, Promotes Glioblastoma Progression Through Transducing IL-6/gp130 Signaling to Activate STAT3 Signaling

  2021cites this paper
• NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells.

  2021cites this paper
• The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma

  2021cites this paper
• Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study

  2020cites this paper
• Doxorubicin-polyglycerol-nanodiamond conjugates disrupt STAT3/IL-6-mediated reciprocal activation loop between glioblastoma cells and astrocytes.

  2020cites this paper
• Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review

  2020cites this paper
• STAT3 transcription factor as target for anti-cancer therapy

  2020cites this paper
• Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways

  2020cites this paper
• STAT3 inhibition induced temozolomide-resistant glioblastoma apoptosis via triggering mitochondrial STAT3 translocation and respiratory chain dysfunction.

  2020cites this paper
• Peroxisome proliferator-activated receptor gamma as a theragnostic target for mesenchymal-type glioblastoma patients

  2020cites this paper
• PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response

  2020cites this paper
• Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells

  2020cites this paper
• Considering the Experimental Use of Temozolomide in Glioblastoma Research

  2020cites this paper
• Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres

  2020cites this paper
• Pulsed and Discontinuous Electromagnetic Field Exposure Decreases Temozolomide Resistance in Glioblastoma by Modulating the Expression of O6-Methylguanine-DNA Methyltransferase, Cyclin-D1, and p53

  2020cites this paper
• Critical appraisal of MGMT in digestive NET treated with alkylating agents.

  2020cites this paper
• Snail expression contributes to temozolomide resistance in glioblastoma.

  2019cites this paper
• PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma.

  2019cites this paper
• Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond

  2019cites this paper
• Signal transduction pathways and resistance to targeted therapies in glioma.

  2019cites this paper
• Cul4 E3 ubiquitin ligase regulates ovarian cancer drug resistance by targeting the antiapoptotic protein BIRC3

  2019cites this paper
• A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine

  2019cites this paper
• How Cancer Cells Resist Chemotherapy: Design and Development of Drugs Targeting Protein-Protein Interactions.

  2019cites this paper
• Combined Inhibition of HDAC and EGFR Reduces Viability and Proliferation and Enhances STAT3 mRNA Expression in Glioblastoma Cells

  2019cites this paper
• Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p

  2019cites this paper
• Current approaches and challenges in the molecular therapeutic targeting of glioblastoma.

  2019cites this paper
• Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors

  2019cites this paper
• Blockade of STAT3 Signaling Contributes to Anticancer Effect of 5-Acetyloxy-6,7,8,4′-Tetra-Methoxyflavone, a Tangeretin Derivative, on Human Glioblastoma Multiforme Cells

  2019cites this paper
• Precision oncology : oncogenic stat3 signalling in brain tumours

  2019cites this paper
• Antitumor activity of novel pyrazole-based small molecular inhibitors of the STAT3 pathway in patient derived high grade glioma cells

  2019cites this paper
• The miR-26a/AP-2α/Nanog signaling axis mediates stem cell self-renewal and temozolomide resistance in glioma

  2019influential citation